Bridges on the Dismissal of the Novartis Patent Challenge

Media Article 7 Sep 2007

Tahir Amin, director of the Initiative for Medicines, Access and Knowledge (I-MAK), told Bridges that “the real issue lies in how the IPAB will define efficacy. This is what will determine the scope of patenting in India and thus the extent to which incremental innovations will be protected”.

Read the full story here.

Partner with us now to build
a more just and equitable
medicine system for all.